Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

AC Immune SA (ACIU) CHF0.02

Sell:$5.20 Buy:$5.21 Change: $0.06 (1.14%)
Market closed |  Prices as at close on 25 November 2020 | Switch to live prices |
Sell:$5.20
Buy:$5.21
Change: $0.06 (1.14%)
Market closed |  Prices as at close on 25 November 2020 | Switch to live prices |
Sell:$5.20
Buy:$5.21
Change: $0.06 (1.14%)
Market closed |  Prices as at close on 25 November 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Contact details

Address:
EPFL Innovation Park, Building B
LAUSANNE
1015
Switzerland
Telephone:
+41 (21) 3459121
Website:
https://www.acimmune.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ACIU
ISIN:
CH0329023102
Market cap:
$377.36 million
Shares in issue:
71.86 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Switzerland
Currency:
US dollar
Indices:
n/a

Key personnel

  • Andrea Pfeifer
    Chief Executive Officer, Co-Founder, Director
  • Joerg Hornstein
    Chief Financial Officer
  • Piergiorgio Donati
    Chief Technical Operations Officer
  • Jean-Fabien Monin
    Chief Administrative Officer
  • Marie Kosco-Vilbois
    Chief Scientific Officer
  • Johannes Streffer
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.